MedTrace Logo

Calcifediol in the Treatment of SARS-CoV-2 Disease (COVID-19).

NCT06279910 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 230

Last updated 2025-06-05

No results posted yet for this study

Summary

Descriptive, retrospective, observational, anonymous, study to evaluate the potential effect of incorporating calcifediol into the therapeutic protocol of patients hospitalized for COVID-19 on mortality and other outcome variables, such as admission to the Intensive Care Unit (ICU), to "Complejo Hospitalario Universitario de Albacete" (CHUA). Albacete (Spain)", based on the files of the MXXI medical records, Information System of the Laboratory (ISL) and Pharmacy.

Conditions

  • SARS-CoV 2 Pneumonia

Interventions

DRUG

Calcifediol

Calcifediol added as a treatment to the rest of the prescribed drugs of the protocol

Sponsors & Collaborators

  • Complejo Hospitalario Universitario de Albacete

    lead OTHER

Principal Investigators

  • Javier Torres, PhD · Complejo Hospitalario Universitario de Albacete. Albacete. Spain

  • Jose M Quesada, MD · Maimónides Biomedical Research Institute of Córdoba (IMIBIC). Córdoba. Spain

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-21
Primary Completion
2024-03-21
Completion
2024-04-25

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06279910 on ClinicalTrials.gov